Ryan Dietz

Corporate Officer/Principal chez Florida State University

Profil

Ryan Dietz is a partner in TIO Bioventures, bringing more than 20 years of experience in technology evaluation, intellectual property generation, licensing and partnering transactions, and company formation efforts to the firm.
Ryan also serves as Vice President, Corporate Development of TIO Bioventures’ flagship portfolio company Treadwell Therapeutics.
Prior to joining TIO, Ryan was a licensing executive with Boston Children’s Hospital, where he oversaw the hospital’s two largest research programs across all stages of development.
During his industry career, Ryan led technology development and intellectual property generation efforts for various prominent start-up biotechnology and pharmaceutical companies including Moderna, Scholar Rock, Magenta Therapeutics, and Morphic Therapeutic.
Each of these companies successfully completed IPOs in 2018 or 2019, including the largest IPO in biotechnology history with Moderna raising $620M at a $7.5B valuation.
Ryan also has extensive business development and alliance management experience and is an inventor and developer of multiple consumer products for musicians.
He holds a Bachelor of Arts degree in psychology and criminal justice from Indiana University Bloomington, and a JD in intellectual property and licensing from Suffolk University Law School.

Postes actifs de Ryan Dietz

Sociétés	Poste	Début
Florida State University	Corporate Officer/Principal	-
Tio Bioventures	Private Equity Investor	01/01/2020
Treadwell Therapeutics, Inc.	Corporate Officer/Principal	01/01/2020

Anciens postes connus de Ryan Dietz

Sociétés	Poste	Fin
Immune Disease Institute, Inc.	Directeur/Membre du Conseil	31/12/2012

Formation de Ryan Dietz

Indiana University Bloomington	Undergraduate Degree
Boston University	Undergraduate Degree
Suffolk University	Graduate Degree